BackBenitec Biopharma Overview

Benitec Biopharma Total Liabilities

Track Benitec Biopharma's total liabilities ($3.7M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$3.67M
↓ 51.98% YoYΔ $-3.97M vs prior year quarter

Peer average

Loading

Benitec Biopharma Total Liabilities History

Loading

Benitec Biopharma vs. peers: Total Liabilities Comparison

Loading

Benitec Biopharma Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Benitec Biopharma (BNTC) FAQ

The latest total liabilities for BNTC is $3.7M as of March 2026. That compares with $7.6M in the prior-year period — down 52.0% year over year. Investors often review this figure alongside Benitec Biopharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, BNTC's total liabilities moved from $7.6M to $3.7M — a 52.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Benitec Biopharma's operating scale or balance-sheet position.

A total liabilities figure of $3.7M for BNTC is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting BNTC's total liabilities ($3.7M), review year-over-year change from $7.6M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.